KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other financing activities (2016 - 2023)

Historic Other financing activities for Ionis Pharmaceuticals (IONS) over the last 8 years, with Q3 2023 value amounting to $517000.0.

  • Ionis Pharmaceuticals' Other financing activities fell 1972.05% to $517000.0 in Q3 2023 from the same period last year, while for Dec 2024 it was $517000.0, marking a year-over-year decrease of 7274.64%. This contributed to the annual value of $14.2 million for FY2023, which is 2941.66% up from last year.
  • Ionis Pharmaceuticals' Other financing activities amounted to $517000.0 in Q3 2023, which was down 1972.05% from $736000.0 recorded in Q4 2022.
  • Ionis Pharmaceuticals' 5-year Other financing activities high stood at $15.3 million for Q1 2021, and its period low was $367000.0 during Q2 2020.
  • For the 5-year period, Ionis Pharmaceuticals' Other financing activities averaged around $3.6 million, with its median value being $517000.0 (2023).
  • In the last 5 years, Ionis Pharmaceuticals' Other financing activities skyrocketed by 158447.89% in 2019 and then crashed by 9083.67% in 2020.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Other financing activities stood at $401000.0 in 2019, then grew by 12.22% to $450000.0 in 2020, then decreased by 2.22% to $440000.0 in 2021, then soared by 67.27% to $736000.0 in 2022, then fell by 29.76% to $517000.0 in 2023.
  • Its last three reported values are $517000.0 in Q3 2023, $736000.0 for Q4 2022, and $644000.0 during Q3 2022.